Valuation: AbbVie Inc.

Market Cap 501B 457B 421B 383B 719B 46,440B 758B 5,118B 2,037B 25,309B 1,880B 1,841B 79,445B P/E 2026 *
36.1x
P/E 2027 * 26.6x
Enterprise Value 564B 515B 474B 431B 809B 52,299B 853B 5,763B 2,294B 28,501B 2,117B 2,073B 89,467B EV / Sales 2026 *
8.33x
EV / Sales 2027 * 7.5x
Free-Float
95.64%
Yield 2026 *
2.43%
Yield 2027 * 2.56%
1 day+0.94%
1 week-2.80%
Current month-2.95%
1 month+1.25%
3 months+7.61%
6 months+33.89%
Current year+25.26%
1 week 279.88
Extreme 279.88
301.2
1 month 278.01
Extreme 278.01
302.93
Current year 190.75
Extreme 190.75
302.93
1 year 190.75
Extreme 190.75
302.93
3 years 137.65
Extreme 137.65
302.93
5 years 115.01
Extreme 115.01
302.93
10 years 58.6
Extreme 58.6
302.93
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO 59 23/06/2022
Chief Tech/Sci/R&D Officer - 01/03/2024
Director TitleAgeSince
Director/Board Member 65 01/01/2013
Director/Board Member 74 01/01/2013
Director/Board Member 69 01/01/2013
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 A Free

Director

59 0.0000%
9/30/26 A Free

Director

129 0.0000%
8/14/26 A Exercice

Executive/Senior Manager

98,130 0.0056%
Change 5-day change 1-year change 3-year change Capi.($)
+0.94%-2.80%+22.88%+106.94% 501B
-0.30%-5.62%+28.35%+127.66% 1,204B
+1.25%-4.60%+33.56%+80.57% 643B
-0.60%-2.39%+27.92%+67.00% 378B
+0.69%-9.00%+40.68%+31.42% 327B
+0.41%-4.81%+24.99%+51.91% 285B
+0.81%-3.72%-1.35%+30.72% 270B
-0.15%-6.73%+27.23%+64.15% 237B
-0.06%-0.91%+29.95%+120.58% 207B
-0.25%-4.08%-14.86%-61.90% 172B
Average +0.34%-4.35%+21.93%+61.91% 422B
Weighted average by Cap. +0.43%-4.67%+25.54%+82.21%

Financials

2026 *2027 *
Net sales 67.79B 61.82B 56.92B 51.81B 97.21B 6,282B 102B 692B 276B 3,423B 254B 249B 10,746B 74.02B 67.5B 62.14B 56.57B 106B 6,859B 112B 756B 301B 3,738B 278B 272B 11,733B
Net income 14.35B 13.09B 12.05B 10.97B 20.58B 1,330B 21.69B 147B 58.34B 725B 53.84B 52.7B 2,275B 19.32B 17.62B 16.22B 14.76B 27.7B 1,790B 29.2B 197B 78.53B 976B 72.47B 70.95B 3,062B
Net Debt 63.23B 57.66B 53.08B 48.32B 90.66B 5,858B 95.58B 646B 257B 3,193B 237B 232B 10,022B 54.29B 49.51B 45.58B 41.49B 77.84B 5,030B 82.07B 554B 221B 2,741B 204B 199B 8,605B
Projected Income Statement - Annual - AbbVie Inc.
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
20/11/26 $286.20 +0.94% 8,670,610
19/11/26 $283.54 -0.86% 5,047,453
18/11/26 $286.01 -2.33% 4,842,258
17/11/26 $292.82 -0.59% 3,950,014
16/11/26 $294.55 -0.16% 5,493,798
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
MarketScreener Ratings - AbbVie Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
283.54USD
Average target price
315.88USD
Spread / Average Target
+11.41%
  1. Stock Market
  2. Stocks
  3. ABBV Stock